Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis by Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati

Get full text

220 Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab by Wolfram Samlowski, Robert Nicholas, Tayla Poretta, Andriy Moshyk, Jonathan Rajkumar, Anthony Salvatore, Esmond Nwokeji

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma by Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber

Get full text

308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma by Dirk Schadendorf, Mark Middleton, Jeffrey Weber, Delphine Hennicken, Paolo Ascierto, Andriy Moshyk, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma by Victoria Federico Paly, Murat Kurt, Lirong Zhang, Marcus O. Butler, Olivier Michielin, Adenike Amadi, Emma Hernlund, Helen M. Johnson, Srividya Kotapati, Andriy Moshyk, John Borrill

Get full text

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 by James Larkin, Jedd Wolchok, David F McDermott, Michael A Postow, Ahmad A Tarhini, Michael B Atkins, F Stephen Hodi, Corey Ritchings, Brian Stwalley, Andriy Moshyk, Meredith M Regan, Charlene M Mantia, Lillian Werner, Sandra Re, Wim van Dijck

Get full text